Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer

Epirubicin, cisplatin and continuous infusion of 5-FU is a widely used palliative regimen in patients with gastric cancer. If cisplatin is substituted by oxaliplatin and 5-FU by capecitabine this regimen can be administered in the outpatient setting. Dose-limiting toxicity of oxaliplatin is peripher...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Schønnemann, K R, Jensen, H A, Yilmaz, M, Jensen, B V, Larsen, O, Pfeiffer, P
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2008
Soggetti:
Clinical Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2538753/
https://ncbi.nlm.nih.gov/pubmed/19238627
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604569
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi